Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data

American Journal of Hematology

Volumn 89, Issue 3, 2014, Pages 249-255

  Baliakas, Panagiotis ^a,b   Iskas, Michalis ^a   Gardiner, Anne ^c   Davis, Zadie ^c   Plevova, Karla ^d   Nguyen Khac, Florence ^e   Malcikova, Jitka ^d   Anagnostopoulos, Achilles ^a   Glide, Sharron ^c   Mould, Sarah ^c   Stepanovska, Kristina ^d   Brejcha, Martin ^f   Belessi, Chrysoula ^g   Davi, Frederic ^e   Pospisilova, Sarka ^d   Athanasiadou, Anastasia ^a   Stamatopoulos, Kostas ^a,b,h   Oscier, David ^c  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b UPPSALA UNIVERSITY   (Sweden)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d CENTRAL EUROPEAN INSTITUTE OF TECHNOLOGY   (Czech Republic)

^e SORBONNE UNIVERSITÉ   (France)

^f J G Mendel Cancer Center Novy Jicin   (Czech Republic)

^g GENERAL HOSPITAL OF NIKEA   (Greece)

^h INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ARTICLE; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 18Q; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRISOMY 12;

CELL CULTURE TECHNIQUES; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKPOINTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; KAPLAN-MEIER ESTIMATE; KARYOTYPE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PROPORTIONAL HAZARDS MODELS; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 84896830468     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23618     Document Type: Article

References (60)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
3. Stamatopoulos K, Ghia P, Rosenquist R. New Biological Prognostic Markers in Chronic Lymphocytic Leukemia. Milan, Wolters: Kluwer Health Italy Ltd.; 2010.
4. Oscier D. Chronic Lymphocytic Leukemia. Do we need novel prognostic markers? In: Hematology Education: The Education Program for the Annual Congress of The European Hematology Association 2013;7:121-130.
5. Rosenquist R, Cortese D, Bhoi S, et al. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk Lymphoma 2013;54(11):2351-2364.
6. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724.
7. Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res ClinHaematol 2010;23:71-84.
8. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
9. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
10. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117-124.
11. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. European Research Initiative on CLL (ERIC). Leukemia 2012;26:1458-1461.
12. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121:1403-1412.
13. Wan Y, Wu CJ. SF3B1 mutations in chronic lymphocytic leukemia. Blood 2013;121:4627-4634.
14. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood 2013;121:4902-4905.
15. Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset Leukemia 2013 May 3; doi: 10.1038/leu.2013.98.
16. Oscier DG, Stevens J, Hamblin TJ, et al. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol 1990;76:352-358.
17. Oscier D, Fitchett M, Herbert T, et al. Karyotypic evolution in B-cell chronic lymphocytic leukaemia. Genes Chromosomes Cancer 1991 Jan;3(1):16-20.
18. Datta T, Bauchinger M, Emmerich B, et al. Chromosome analyses in chronic lymphocytic leukemia and related B-cell neoplasms. Cancer Genet Cytogenet 1991;55:49-56.
19. Athanasiadou A, Stamatopoulos K, Tsompanakou A, et al. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. Cancer Genet Cytogenet 2006;168:109-119.
20. Haferlach C, Bacher U. Cytogenetic methods in chronic lymphocytic leukemia. Methods Mol Biol 2011;730:119-130.
21. Rigolin GM, Cibien F, Martinelli S, et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. Blood 2012;119:2310-2313.
22. Heerema NA, Byrd JC, Dal Cin PS, et al. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study, Chronic Lymphocytic Leukemia Research Consortium. Cancer Genet Cytogenet 2010;203:134-140.
23. Mian M, Rinaldi A, Mensah AA, et al. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Ann Oncol 2013;24:1378-1384.
24. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012;120:4783-4794.
25. Schweighofer CD, Coombes KR, Majewski T, et al. Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes. J Mol Diagn 2013;15:196-209.
26. Gunnarsson R, Mansouri L, Rosenquist R. Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies. Leuk Lymphoma 2013;54(8):1583-1590.
27. Ramsay AJ, Martínez-Trillos A, Jares P, et al. Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. Clin Transl Oncol 2013;15:3-8.
28. Sobreira NL, Gnanakkan V, Walsh M, et al. Characterization of complex chromosomal rearrangements by targeted capture and next-generation sequencing. Genome Res 2011;21:1720-1727.
29. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-751.
30. Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442-2551.
31. Van Den Neste E, Robin V, Francart J, et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 2007;21:1715-1722.
32. Klein IA, Resch W, Jankovic M, et al. Translocation-capturesequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. Cell 2011;147:95-106.
33. Oliveira TY, Resch W, Jankovic M, et al. Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements. J Immunol Methods 2012;375:176-181.
34. Walker BA, Wardell CP, Johnson DC, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 2013;121:3413-3419.
35. Shaffer L SM, Campbel L. ISCN: An International System for Human Cytogenetic Nomenclature, Basel, Switzerland: S. Karger Publishers, Inc.; 2009.
36. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008;111:1524-1533.
37. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012;119:4467-4475.
38. Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009;37:D1006-D1012.
39. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008;36:W503-W508.
40. Ibbotson R, Athanasiadou A, Sutton LA, et al. Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant. Leukemia 2012;26:170-172.
41. Cavazzini F, Hernandez JA, Gozzetti A, et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 2008;142:529-537.
42. Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer 2013;13:443-454.
43. Chiarle R, Zhang Y, Frock RL, et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 2011;147:107-119.
44. Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu Rev Immunol 2011;29:319-350.
45. Lin C, Yang L, Rosenfeld MG. Molecular logic underlying chromosomal translocations, random or non-random? Adv Cancer Res 2012;113:241-279.
46. Lu G, Kong Y, Yue C. Genetic and immunophenotypic profile of IGH at rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010;196:56-63.
47. Huh YO, Schweighofer CD, Ketterling RP, et al. Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. Am J Clin Pathol 2011;135:686-696.
48. Alt FW, Zhang Y, Meng FL, et al. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell 2013;152:417-429.
49. Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell 2010;14, 127-14, 138.
50. Gazumyan A, Bothmer A, Klein IA, et al. Activation-induced cytidine deaminase in antibody diversification and chromosome translocation. Adv Cancer Res 2012;113:167-190.
51. Robbiani DF, Nussenzweig MC. Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 2013;8:79-103.
52. Robbiani DF, Bunting S, Feldhahn N, et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell 2009;36:631-641.
53. Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-2597.
54. Palacios F, Moreno P, Morande P, et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood 2010;115:4488-4496.
55. Patten PE, Chu CC, Albesiano E, et al. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. Blood 2012;120:4802-4811.
56. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012;119:329-331.
57. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012;97:437-441.
58. Badoux XC, Keating MJ, Wang X, et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 2011;118:2085-2093.
59. Haferlach C, Dicker F, Weiss T, et al. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer 2010;49:851-859.
60. Jaglowski SM, Ruppert AS, Heerema NA, et al. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol 2012 Oct;159:82-87.